Dong Shuai, Yu Ji-Ren, Zhang Qin, Liu Xiao-Sun
a Department of General Surgery, The First Affiliated Hospital , College of Medicine, Zhejiang University , China.
J Chemother. 2016;28(1):59-64. doi: 10.1179/1973947815Y.0000000028.
This study aimed to evaluate the efficacy of FOLFOX6, SOX and XELOX as neoadjuvant chemotherapy for advanced gastric cancer. The study retrospectively assessed clinicopathological data of patients who received a radical D2 gastrectomy for gastric cancer from January 2010 to January 2013.The patients were either not administered neoadjuvant chemotherapy (control) or were given FOLFOX6, SOX and XELOX prior to surgery. The metastatic rate was also higher for the control group compared with the three chemotherapy regimens in N2 station lymph nodes (P < 0.001). The SOX group had significantly lower metastatic total and N2 station lymph nodes than FOLFOX6 and XELOX (P < 0.01). The frequency of metastatic lymph nodes relative to total lymph nodes examined was 9.9, 6.6, 3.9 and 5.3% for control, FOLFOX6, SOX and XELOX groups, respectively. In conclusion, SOX may be the most effective of these treatments as preoperative chemotherapy for Chinese patients with advanced gastric cancer.
本研究旨在评估FOLFOX6、SOX和XELOX作为晚期胃癌新辅助化疗的疗效。该研究回顾性评估了2010年1月至2013年1月期间接受胃癌根治性D2胃切除术患者的临床病理数据。患者要么未接受新辅助化疗（对照组），要么在手术前接受FOLFOX6、SOX和XELOX治疗。与三种化疗方案相比，对照组在N2站淋巴结的转移率也更高（P < 0.001）。SOX组的总转移淋巴结和N2站淋巴结明显低于FOLFOX6和XELOX组（P < 0.01）。对照组、FOLFOX6组、SOX组和XELOX组相对于检查的总淋巴结的转移淋巴结频率分别为9.9%、6.6%、3.9%和5.3%。总之，对于中国晚期胃癌患者，SOX作为术前化疗可能是这些治疗中最有效的。
